Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tenogenic primed mesenchymal stem cells
- Development stage
- Unknown
- Lead developer
- Boehringer Ingelheim
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intralesional
01
Overview
Tenogenic primed mesenchymal stem cells (tpMSCs) are a specialized veterinary cell therapy developed for the treatment of tendon and suspensory ligament injuries in horses. Unlike naive mesenchymal stem cells, these cells undergo a proprietary in vitro "priming" process that pre-differentiates them toward a tenogenic (tendon-forming) lineage before administration. This priming is designed to enhance their regenerative capacity and ensure they produce high-quality, functional tendon tissue rather than non-functional scar tissue. Clinical studies, including ultrasound tissue characterization (UTC) and histological analysis, have demonstrated that tpMSCs significantly improve collagen fiber alignment and increase the ratio of Collagen Type I to Collagen Type III in healed tendons. The primary commercial product, RenuTend, was developed by Global Stem cell Technology (GST) and is currently marketed by Boehringer Ingelheim following its acquisition of GST. It is administered via a single intralesional injection under ultrasound guidance.
- Brand names
- RenuTend
- Other names
- equine allogeneic tenogenic primed mesenchymal stem cellsallogeneic tenogenic primed mesenchymal stem cells
Beyond the preview
Go deeper on tenogenic primed mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tenogenic primed mesenchymal stem cells.